Peptides & Performance
NAD+ INJECTIONS VS NMN SUPPLEMENTS: WHICH SHOULD YOU CHOOSE?
The NAD+ space is confusing. Injectable NAD+, oral NMN, oral NR, liposomal NAD+, patches — everyone claims their method is best. Here's what the evidence actually says.
Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC · Updated March 25, 2026
HEAD-TO-HEAD
| NAD+ Injections | NMN (Oral) | NR (Oral) | |
|---|---|---|---|
| What It Is | Direct NAD+ delivered subcutaneously | NAD+ precursor (one step away) | NAD+ precursor (two steps away) |
| Bioavailability | High (bypasses gut) | Low-moderate (gut absorption, then conversion) | Low-moderate (similar to NMN) |
| Evidence Level | Emerging (limited human RCTs) | Growing (several human trials incl. Yoshino 2021) | Moderate (Martens 2018, others) |
| Cost | $60/shot at Moonshot | $40-80/month | $30-60/month |
| Convenience | Clinic visit, 5 min | Daily pill at home | Daily pill at home |
| Medical Oversight | Yes (prescribed, monitored) | No (OTC supplement) | No (OTC supplement) |
| Speed of Effect | Days to weeks | Weeks to months | Weeks to months |
| FDA Status | Compounded (503A pharmacy) | Dietary supplement (FDA reinstated NDI status 2025) | Dietary supplement |
HOW EACH WORKS
All three approaches share the same goal: raise NAD+ levels in your cells. They take different paths to get there, and each path has trade-offs.
NAD+ Injections — Direct Delivery
Subcutaneous injection delivers NAD+ directly into tissue. The molecule bypasses gut absorption entirely. It does not need to be converted — it IS the end product your cells use for energy production, DNA repair, and sirtuin activation.
However, questions remain about how much injected NAD+ actually enters cells intact versus being broken down extracellularly into nicotinamide. NAD+ is a large molecule, and the enzyme CD73 on cell surfaces can dephosphorylate it before cellular uptake. This does not mean injections are ineffective — the resulting metabolites still feed back into NAD+ synthesis pathways — but it means the story is more nuanced than "inject NAD+ and it goes straight into your cells."
NMN — One Step Away
Nicotinamide mononucleotide is converted to NAD+ by the enzyme NMNAT. It is one enzymatic step from the end product. Oral NMN must survive stomach acid, be absorbed through the gut lining, and then be converted. Bioavailability is lower than injectable delivery, but multiple human trials have shown that oral NMN does raise blood NAD+ levels.
Recent research suggests NMN may also enter cells directly via the SLC12A8 transporter, a dedicated NMN transport channel identified in 2019. This pathway remains debated — some labs have replicated the finding, others have not. If confirmed, it would mean NMN has a more direct route into cells than previously assumed. Either way, oral NMN reliably raises NAD+ metabolites in human studies.
NR — Two Steps Away
Nicotinamide riboside is converted first to NMN (by NR kinases), then to NAD+ (by NMNAT). Two enzymatic steps from the end product. It faces similar gut absorption challenges as NMN. ChromaDex's Niagen (Tru Niagen) is the most-studied NR product, with several published human trials demonstrating safety and NAD+ elevation.
NR was the first NAD+ precursor to gain significant research attention and has a longer track record of human safety data than NMN. The two-step conversion is not necessarily a disadvantage — NR kinases are widely expressed, and the conversion is efficient in most tissues.
The practical takeaway: All three methods raise NAD+ levels. They differ in route of delivery, convenience, cost, and the amount of published evidence behind them. None has been definitively proven superior to the others for long-term clinical outcomes in humans. That is the honest state of the science. For a deeper dive on NAD+ biology and why it matters, see our comprehensive NAD+ guide.
WHAT THE EVIDENCE SAYS
This is where we need to be straight with you. The evidence base is not equal across these three options, and being honest about that is more useful than pretending otherwise.
NMN: The Most Human Trial Data
NMN currently has the most published human clinical trial data of the three options. The landmark study is Yoshino et al. 2021, published in Science: a randomized, double-blind, placebo-controlled trial showing that 250mg/day NMN for 10 weeks improved skeletal muscle insulin sensitivity in prediabetic postmenopausal women. This was a well-designed trial in a top-tier journal.
Beyond Yoshino, multiple human trials have demonstrated that oral NMN safely raises blood NAD+ levels at doses ranging from 100-1200mg/day. Poddar et al. (2023) published a systematic review of NMN clinical trials, documenting consistent NAD+ elevation and favorable safety profiles across studies. Liao et al. (2021) showed NMN supplementation enhanced aerobic capacity in amateur runners.
Limitations: Most NMN trials are small (under 100 participants), short-term (8-12 weeks), and many are funded by supplement companies. We do not yet have large, long-term, independently funded RCTs for hard clinical endpoints like cardiovascular events, cognitive decline, or mortality. The evidence is promising and growing — but not definitive.
NR: Moderate Evidence
Martens et al. (2018) conducted a crossover trial showing that 1000mg/day NR (Niagen) for 6 weeks raised NAD+ levels by approximately 60% in healthy older adults and was well-tolerated. Dollerup et al. (2018) found NR improved body composition markers in obese men, though the effects were modest.
Conze et al. (2019) established safety across a range of doses. Airhart et al. (2017) documented NR pharmacokinetics in humans, showing dose-dependent increases in blood NAD+ metabolites.
Limitations: Peter Attia has publicly noted that the NIA Interventions Testing Program (ITP) — one of the most rigorous lifespan testing programs in aging research — found no lifespan benefit from NR in mice. This does not mean NR is useless in humans, but it is a data point worth acknowledging. NR also faces the same "small trial, short duration" limitations as NMN.
Injectable NAD+: Emerging Evidence
Injectable NAD+ — whether subcutaneous or intravenous — has limited published human clinical trial data compared to NMN and NR. The biological rationale is strong: bypassing gut absorption should deliver more NAD+ to the bloodstream than oral routes. Clinical experience across practices that offer it (including ours) is consistently favorable, with patients reporting improvements in energy, mental clarity, and recovery.
A 2019 pilot study on IV NAD+ raised important questions about clearance. Plasma NAD+ levels did not rise until approximately 2 hours into a 6-hour infusion, and urinary excretion of NAD+ metabolites increased at the 6-hour mark. This suggests rapid extracellular metabolism — meaning some of the infused NAD+ may be broken down before entering cells, with the resulting metabolites (nicotinamide, NMN) feeding back into intracellular NAD+ synthesis.
Honest take: Injectable NAD+ has the strongest theoretical rationale for bioavailability but the least published clinical trial data of the three options. We believe the mechanism is sound, the safety profile is favorable, and the patient experience is positive. But we would be overselling it to claim the clinical evidence matches what NMN and NR have published. That gap will likely close as more trials are conducted.
Why this honesty matters: Clinics that oversell injectable NAD+ as "proven to reverse aging" are doing patients a disservice. The mechanistic evidence is strong. The animal data is compelling. The human data is accumulating. But conflating "strong biological rationale" with "proven in large human trials" is the kind of overreach that erodes trust. We would rather you make an informed choice based on what the science actually shows.
THE BIOAVAILABILITY QUESTION
This is the core debate in the NAD+ space, and it deserves a straight answer rather than marketing spin.
The argument for injections: Subcutaneous delivery bypasses the gut entirely. No stomach acid degradation. No first-pass liver metabolism. No reliance on gut health or absorption capacity. The full dose enters tissue directly. For a molecule as large and unstable as NAD+, this matters.
The counterargument: Does it matter that injections bypass the gut if most NAD+ is broken down extracellularly anyway? The enzyme CD38 on cell surfaces and in the bloodstream rapidly metabolizes NAD+. Some researchers argue that injected NAD+ is largely converted to nicotinamide before it enters cells — and nicotinamide is the same precursor you could get from a cheap supplement.
The counter-counterargument: Even if some injected NAD+ is degraded extracellularly, the resulting metabolites (nicotinamide, NMN) still feed back into NAD+ synthesis pathways via the salvage pathway. And subcutaneous delivery creates a depot effect — a reservoir of NAD+ that is absorbed gradually from the injection site, providing sustained delivery rather than a single bolus that gets rapidly cleared.
Current scientific consensus: "It's complicated." No single delivery method has definitive proof of superiority for clinical outcomes in humans. The bioavailability advantage of injections is real at the pharmacokinetic level, but whether that translates to meaningfully better outcomes than oral precursors is an open question.
Practical conclusion: Injectable NAD+ offers the most direct route. Oral precursors are the most studied. Both appear to raise NAD+ levels. The best choice depends on your goals, budget, and preference — not on any one method being categorically "proven better."
WHEN TO CHOOSE INJECTABLE NAD+
You want the fastest route to NAD+ elevation
Subcutaneous delivery puts NAD+ directly into tissue without waiting for gut absorption and enzymatic conversion. If speed matters — for example, during a targeted loading phase — injections get you there faster.
You're already at a clinic for hormone optimization or other services
If you are already coming to Moonshot for hormone therapy, DEXA scans, or other clinical services, adding an NAD+ injection takes 5 minutes. The marginal time cost is minimal, and NAD+ supports the same metabolic pathways that optimized hormones activate.
You prefer a clinician-administered protocol with medical oversight
Injectable NAD+ is prescribed, compounded by a 503A pharmacy, and administered under clinical supervision. Your provider monitors your response and adjusts dosing. This level of oversight does not exist with OTC supplements.
You've tried oral supplements without noticeable benefit
Some patients take NMN or NR for months without perceiving a difference. This could be a gut absorption issue, a conversion efficiency issue, or simply individual variation. Switching to injectable delivery removes the absorption variable from the equation.
You want 5-minute sessions instead of daily pills
Some people prefer a weekly or biweekly clinic visit over adding another daily supplement to their routine. Compliance is higher when the intervention happens at a scheduled appointment rather than relying on daily self-administration.
WHEN TO CHOOSE ORAL NMN OR NR
You prefer the convenience of a daily pill
Oral NMN or NR is taken at home, on your own schedule, with no clinic visits required. For people who travel frequently or live far from a clinic, this is a significant practical advantage.
Budget is a primary factor
Quality NMN runs $40-80/month. Quality NR (Tru Niagen) runs $30-60/month. Weekly NAD+ injections run $240/month. If you are optimizing for cost-effectiveness, oral precursors deliver NAD+ elevation at a fraction of the price.
You want the most-studied option
NMN has the most published human trial data of the three approaches. If you prioritize interventions with the deepest clinical evidence base, NMN currently wins on that criterion. NR is a close second.
You're using it for long-term maintenance after a loading phase
Some patients do a 2-4 week loading phase with injectable NAD+ (1-2x per week), then transition to daily oral NMN for ongoing maintenance. This combines the advantages of both: rapid initial elevation via injection, then sustained levels via oral supplementation at lower cost.
You don't have access to a clinic that offers injectable NAD+
Not everyone lives near a clinic that provides compounded NAD+ injections. Oral NMN and NR are available online and in health food stores without a prescription. Access should not be a barrier to NAD+ support.
COST COMPARISON
| Monthly Cost | Annual Cost | |
|---|---|---|
| NAD+ Injections (Moonshot, weekly) | $240 | $2,880 |
| NAD+ Injections (Moonshot, biweekly) | $120 | $1,440 |
| NAD+ IV Drip (typical clinic, monthly) | $500-1,500 | $6,000-18,000 |
| NMN oral (quality brand) | $40-80 | $480-960 |
| NR oral (Niagen / Tru Niagen) | $30-60 | $360-720 |
Combination approach: Some patients use a combination — an injectable loading phase (2-4 weeks of 1-2x/week injections) followed by oral NMN for daily maintenance. This captures the rapid elevation benefit of injections while keeping the ongoing cost closer to oral-only supplementation. Hormone optimization members at Moonshot receive 1 vitamin injection per month included in their membership.
COMMON QUESTIONS
Is NMN or NAD+ better?
Neither is categorically better. They are different tools. NAD+ injections deliver the end product directly, bypassing absorption and conversion. NMN has more published human trial data, including the Yoshino 2021 trial showing improved muscle insulin sensitivity. If you value bioavailability and speed, injections have the edge. If you value clinical evidence depth and convenience, NMN has the edge. Many patients benefit from using both at different phases.
Why are NAD+ injections more expensive than NMN pills?
NAD+ injections require pharmaceutical-grade compounding from a licensed 503A pharmacy, sterile preparation, clinical administration, and medical oversight. NMN supplements are manufactured as dietary supplements with lower regulatory requirements and no clinical visit needed. The price difference reflects the supply chain, regulatory compliance, and professional oversight involved — not necessarily a proportional difference in effectiveness.
Can I take NMN and get NAD+ injections at the same time?
Yes. Some patients use a combination approach — injectable NAD+ for a loading phase followed by oral NMN for daily maintenance between injection appointments. There are no known contraindications to combining the two, since both ultimately feed the same NAD+ pool. Discuss timing and dosing with your provider to optimize the protocol.
Is injectable NAD+ more effective than oral NMN?
Injectable NAD+ bypasses gut absorption entirely, which gives it a theoretical bioavailability advantage. But "more effective" depends on what outcome you are measuring. NMN has demonstrated efficacy in human trials for insulin sensitivity and raising blood NAD+ levels. Injectable NAD+ has less published trial data but strong biological rationale and consistent patient-reported benefits. The honest answer: we do not yet have a head-to-head randomized controlled trial comparing injectable NAD+ to oral NMN for the same clinical endpoints.
What dose of NMN equals one NAD+ injection?
There is no direct dose equivalence because the delivery mechanisms are fundamentally different. An NAD+ injection delivers the molecule directly to the bloodstream at near-100% bioavailability. Oral NMN must survive digestion, be absorbed, and then be enzymatically converted. Typical oral NMN doses range from 250-1000mg daily. A typical subcutaneous NAD+ injection is 100-200mg. But comparing milligrams across different routes is misleading — what matters is the resulting tissue NAD+ levels, and we do not yet have definitive data on that comparison.
Does Moonshot offer NMN or NR supplements?
Moonshot Medical focuses on injectable NAD+ as part of our clinical protocols because the delivery method aligns with our model of medical oversight and precision dosing. We can discuss oral NMN or NR as part of a comprehensive plan during your consultation, and we will give you honest guidance on quality brands if oral supplementation makes sense for your situation. We are not in the business of pushing one approach over another — we are in the business of finding what works for you.
References
- 1. Yoshino M, Yoshino J, Kayser BD, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224-1229.
- 2. Martens CR, Denman BA, Mazzo MR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nat Commun. 2018;9(1):1286.
- 3. Rajman L, Chwalek K, Sinclair DA. "Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence." Cell Metab. 2018;27(3):529-547.
- 4. Imai S, Guarente L. "NAD+ and sirtuins in aging and disease." Trends Cell Biol. 2014;24(8):464-471.
- 5. Mills KF, Yoshida S, Stein LR, et al. "Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice." Cell Metab. 2016;24(6):795-806.
- 6. Massudi H, Grant R, Braidy N, et al. "Age-associated changes in oxidative stress and NAD+ metabolism in human tissue." PLoS One. 2012;7(7):e42357.
- 7. Dollerup OL, Christensen B, Svart M, et al. "A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects." Am J Clin Nutr. 2018;108(2):343-353.
- 8. Conze D, Brenner C, Kruger CL. "Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults." Sci Rep. 2019;9(1):9772.
- 9. Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." J Int Soc Sports Nutr. 2021;18(1):54.
- 10. Yoshino J, Baur JA, Imai S. "NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR." Cell Metab. 2018;27(3):513-528.
- 11. Poddar SK, Sifat AE, Haque S, et al. "Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule." Biomolecules. 2023;13(1):34.
- 12. Braidy N, Berg J, Clement J, et al. "Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases." Antioxid Redox Signal. 2019;30(2):187-207.
- 13. Shade C. "The Science Behind NMN — A Stable, Reliable NAD+ Activator and Anti-Aging Molecule." Integr Med (Encinitas). 2020;19(1):12-14.
- 14. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism." Cell Metab. 2016;23(6):1127-1139.
- 15. Airhart SE, Shireman LM, Risler LJ, et al. "An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers." PLoS One. 2017;12(12):e0186459.
NOT SURE WHICH IS RIGHT FOR YOU?
Injectable NAD+, oral NMN, or a combination — the right approach depends on your goals, your budget, and your biology. Book a consultation and we'll walk through the options honestly, without pushing one over the other.
Book Consultation